Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer
Clinical trial NCT04032418 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04032418
- Sponsor
- Roswell Park Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-13
- Primary completion
- 2025-03-14
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.